Literature DB >> 2053913

The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease.

J T Sharp1, F Wolfe, D M Mitchell, D A Bloch.   

Abstract

Erosions and cartilage destruction are nearly universal features in peripheral joints that have been chronically affected by rheumatoid arthritis. Scoring methods to measure the extent of these abnormalities in hands and wrists have been developed and have been thoroughly tested in several studies to establish their reproducibility. In this study, we utilized one of these scoring methods to examine the progression of radiologic damage as related to duration of disease. Two hundred ninety-two patients from 3 different participating centers in the Arthritis, Rheumatism, and Aging Medical Information System were included. Six hundred fifty films of the hands and wrists, obtained from 210 patients, were scored for erosions and joint space narrowing. The average annual rate of progression of the total radiologic score, which sums erosion and joint space abnormalities and has a maximum possible score of 314, was approximately 4 units per year over the first 25 years after onset; this progression was more rapid in the earlier years of disease and slightly slower in the later years. Data were insufficient to accurately determine the progression rate in disease of more than 25 years duration.

Entities:  

Mesh:

Year:  1991        PMID: 2053913     DOI: 10.1002/art.1780340606

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  44 in total

Review 1.  Anti-TNF agents for rheumatoid arthritis.

Authors:  H E Seymour; A Worsley; J M Smith; S H Thomas
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 2.  Interpreting radiographic data in rheumatoid arthritis.

Authors:  P A Ory
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

Review 3.  Imaging of the hand and wrist in RA.

Authors:  B Taouli; A Guermazi; K E Sack; H K Genant
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

4.  The relation between joint erosion and generalized osteoporosis and disease activity in patients with rheumatoid arthritis.

Authors:  Filiz Sivas; Nurdan Barça; Mustafa Onder; Kürşat Ozoran
Journal:  Rheumatol Int       Date:  2006-04-20       Impact factor: 2.631

5.  Severity of rheumatoid arthritis: the SEVERA study.

Authors:  Rafic Baddoura; Souha Haddad; Hassane Awada; Abdel Fattah Al-Masri; Georges Merheb; Said Attoui; Jad Okais; Jamil Messayke; Fadi Ghandour
Journal:  Clin Rheumatol       Date:  2005-12-15       Impact factor: 2.980

Review 6.  Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature.

Authors:  Gonçalo Boleto; Moustapha Dramé; Isabelle Lambrecht; Jean-Paul Eschard; Jean-Hugues Salmon
Journal:  Clin Rheumatol       Date:  2017-07-01       Impact factor: 2.980

7.  Assessment of phalangeal bone loss in patients with rheumatoid arthritis by quantitative ultrasound.

Authors:  P Röben; R Barkmann; S Ullrich; A Gause; M Heller; C C Glüer
Journal:  Ann Rheum Dis       Date:  2001-07       Impact factor: 19.103

8.  Randomized trial of switching rheumatoid arthritis patients in remission with injectable gold to auranofin.

Authors:  P E Prete; J Zane; M Krailo; M Bulanowski
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

9.  Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes.

Authors:  Y Li; D Li; Y Li; S Wu; S Jiang; T Lin; L Xia; H Shen; J Lu
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

10.  Rho iso-alpha acids from hops inhibit the GSK-3/NF-kappaB pathway and reduce inflammatory markers associated with bone and cartilage degradation.

Authors:  Veera Reddy Konda; Anuradha Desai; Gary Darland; Jeffrey S Bland; Matthew L Tripp
Journal:  J Inflamm (Lond)       Date:  2009-08-27       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.